Literature DB >> 19422587

Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently.

Mark A Crandall1, Benjamin D Horne, John D Day, Jeffrey L Anderson, Joseph B Muhlestein, Brian G Crandall, J Peter Weiss, Donald L Lappé, T Jared Bunch.   

Abstract

BACKGROUND: Inflammation has been shown to have a direct role in the initiation, maintenance, and recurrence of atrial fibrillation (AF) although the underlying mechanisms are unknown. Similarly, it is unclear if inflammatory markers are elevated due to the AF alone or the coexisting cardiovascular diseases that increase the risk of AF.
METHODS: Consecutive patients who underwent angiography for suspicion of coronary artery disease, but without a myocardial infarction, were studied. Serum was analyzed to determine high-sensitivity C-reactive protein (hs-CRP) level. Patients' AF status was determined through ICD-9 codes, review of hospital discharge summaries, clinical evaluations, and electrocardiograms.
RESULTS: A total of 2,340 patients were studied (64+/-12 years). Comorbid diseases included 1,438 (61%) coronary artery disease, 1,309 (56%) hypertension, 433 (19%) diabetes, 345 (15%) congestive heart failure, and 43 (2%) a prior stroke. The hs-CRP level was significantly higher in patients with AF (n = 238) compared to those without (14.0 mg/L vs 9.1 mg/L, P < 0.001). Greater CHADS2 score was also significantly associated with higher hs-CRP in a linear fashion (medians [mg/L], 0: 1.99, 1: 2.91, 2: 3.49, 3: 3.89, 4-5: 4.82, P <0.001). The presence of AF was associated with higher hs-CRP level across all scores (medians [mg/L], 0: 2.22 vs 1.98, P = 0.83, 1: 3.85 vs 2.86, P = 0.057, 2: 4.96 vs 3.29, P = 0.021, 3: 6.29 vs 3.17, P = 0.09, 4-5: 4.82 vs 4.50, P = 0.87).
CONCLUSION: Risks factors associated with AF were associated with higher hs-CRP in an incremental manner. The presence of AF increased hs-CRP across the CHADS2 score strata is supportive of the concept that AF is an inflammatory process and may convey independent risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422587     DOI: 10.1111/j.1540-8159.2009.02339.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  11 in total

Review 1.  Cognitive impairment associated with atrial fibrillation: a meta-analysis.

Authors:  Shadi Kalantarian; Theodore A Stern; Moussa Mansour; Jeremy N Ruskin
Journal:  Ann Intern Med       Date:  2013-03-05       Impact factor: 25.391

Review 2.  Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options.

Authors:  David L Johnson; John D Day; Srijoy Mahapatra; T Jared Bunch
Journal:  J Atr Fibrillation       Date:  2012-02-02

3.  A Circulating Biomarker Risk-Prediction Model Correlates with CHADS-2 Risk Score in Chronic Atrial Fibrillation.

Authors:  Smita I Negi; Ian Greener; Aashish Anand; Samuel C Dudley
Journal:  IJC Metab Endocr       Date:  2015-03

4.  B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.

Authors:  Moritz F Sinner; Katherine A Stepas; Carlee B Moser; Bouwe P Krijthe; Thor Aspelund; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Ramachandran S Vasan; Thomas J Wang; Sunil K Agarwal; David D McManus; Oscar H Franco; Xiaoyan Yin; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Brad C Astor; Christie M Ballantyne; Ron C Hoogeveen; Andrew E Arai; Elsayed Z Soliman; Patrick T Ellinor; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Michael J Pencina; Emelia J Benjamin; Alvaro Alonso
Journal:  Europace       Date:  2014-07-18       Impact factor: 5.214

Review 5.  The impact of atrial fibrillation and its treatment on dementia.

Authors:  Arun Kanmanthareddy; Ajay Vallakati; Arun Sridhar; Madhu Reddy; Hari Priya Sanjani; Jayasree Pillarisetti; Donita Atkins; Sudharani Bommana; Misty Jaeger; Loren Berenbom; Dhanunjaya Lakkireddy
Journal:  Curr Cardiol Rep       Date:  2014-08       Impact factor: 2.931

6.  Relationship of the total atrial conduction time to subclinical atherosclerosis, inflammation and echocardiographic parameters in patients with type 2 diabetes mellitus.

Authors:  Eftal Murat Bakirci; Levent Demirtas; Husnu Degirmenci; Selim Topcu; Selami Demirelli; Hikmet Hamur; Mutlu Buyuklu; Emin Murat Akbas; Adalet Ozcicek; Fatih Ozcicek; Gokhan Ceyhun; Ergun Topal
Journal:  Clinics (Sao Paulo)       Date:  2015-02       Impact factor: 2.365

7.  Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications.

Authors:  T Jared Bunch; Heidi T May; Tami L Bair; Brian G Crandall; Michael J Cutler; John D Day; Victoria Jacobs; Charles Mallender; Jeffrey S Osborn; Scott M Stevens; J Peter Weiss; Scott C Woller
Journal:  J Am Heart Assoc       Date:  2016-07-11       Impact factor: 5.501

8.  Association between vascular comorbidity and progression of Alzheimer's disease: a two-year observational study in Norwegian memory clinics.

Authors:  Rannveig Sakshaug Eldholm; Karin Persson; Maria Lage Barca; Anne-Brita Knapskog; Lena Cavallin; Knut Engedal; Geir Selbaek; Eva Skovlund; Ingvild Saltvedt
Journal:  BMC Geriatr       Date:  2018-05-22       Impact factor: 3.921

Review 9.  Left atrial spontaneous echo contrast: relationship with clinical and echocardiographic parameters.

Authors:  Takahide Ito; Michihiro Suwa
Journal:  Echo Res Pract       Date:  2019-06-01

Review 10.  Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score.

Authors:  Chen-Ying Hung; Yu-Cheng Hsieh; Jin-Long Huang; Ching-Heng Lin; Tsu-Juey Wu
Journal:  Korean Circ J       Date:  2014-07       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.